Capital Group Private Client Services Inc. Acquires 4,879 Shares of Amgen Inc. $AMGN

Key Points

• Capital Group Private Client Services Inc. increased its Amgen stake by 7.0% in the fourth quarter, buying 4,879 additional shares and bringing its total holdings to 74,291 shares worth about $24.3 million.
• Amgen recently reported better-than-expected quarterly results, with EPS of $5.15 versus $4.77 expected and revenue of $8.62 billion, up 5.8% year over year.
• The company also has several positive catalysts, including European approval for IMDYLLTRA and encouraging autoimmune therapy data for UPLIZNA and TAVNEOS, though analyst sentiment remains mixed with a consensus rating of Hold.

Capital Group Private Client Services Inc. grew its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,291 shares of the medical research company's stock after acquiring an additional 4,879 shares during the quarter. Capital Group Private Client Services Inc.'s holdings in Amgen were worth $24,316,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of AMGN. Anfield Capital Management LLC boosted its position in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock valued at $25,000 after acquiring an additional 70 shares during the period. Dogwood Wealth Management LLC boosted its position in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock valued at $25,000 after acquiring an additional 55 shares during the period. Board of the Pension Protection Fund bought a new stake in shares of Amgen in the fourth quarter valued at approximately $26,000. Manning & Napier Advisors LLC boosted its position in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock valued at $32,000 after acquiring an additional 32 shares during the period. Finally, Olistico Wealth LLC bought a new stake in shares of Amgen in the fourth quarter valued at approximately $33,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

Amgen stock opened at $349.58 on Friday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The stock has a fifty day moving average price of $341.35 and a two-hundred day moving average price of $345.47. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The firm has a market capitalization of $188.67 billion, a P/E ratio of 24.33, a P/E/G ratio of 3.51 and a beta of 0.42.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the company posted $4.90 earnings per share. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.85% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

AMGN has been the subject of several research reports. Guggenheim reduced their price objective on Amgen from $351.00 to $340.00 and set a "neutral" rating for the company in a research report on Monday, May 4th. Canaccord Genuity Group began coverage on Amgen in a research report on Monday, April 20th. They issued a "hold" rating and a $366.00 target price for the company. Leerink Partners reaffirmed a "market perform" rating and issued a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. Morgan Stanley set a $332.00 target price on Amgen in a research report on Friday, May 1st. Finally, Royal Bank Of Canada raised their target price on Amgen from $360.00 to $370.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $353.81.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.